Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1189 plus methotrexate in DMARD‑naïve early rheumatoid arthritis
2024-514981-37-00Phase 2Completed
- Sponsor
- SynAct Pharma AB
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of resomelagon in rheumatoid arthritis (RA) (4 arms), sponsored by SynAct Pharma AB. Primary endpoint: Change from baseline in DAS28(CRP) at week 12. Started Nov 2024; status: completed.
02
Drugs
resomelagon
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-514981-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514981-37-00.